Study Summary
This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric patients with B-cell NHL and patients in primary relapse.
Want to learn more about this trial?
Request More InfoInterventions
CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte CellsDRUG
The CD19 CAR used in this study consists of three main components: the variable regions of the anti-CD19 monoclonal antibody FMC63 71, linked to the TNFRSF-19-derived transmembrane domain, the 4-1BB costimulatory molecule, and the signaling domain of the CD3-zeta molecule. The DNA encoding this receptor was cloned into a lentiviral vector (LV) backbone.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Children's Hospital Colorado | Aurora | Colorado | United States |